0.01% to 0.05% Atropine: Low dose atropine is considered to be safe for children. Low dose atropine has been shown to work without increasing pupil size or decreasing near vision dramatically, side ...

(Reuters) -Eyenovia will discontinue a late-stage study for its experimental drug-device combination to treat ...

The Singapore Eye Research Institute now has grants to develop artificial intelligence in treating eye diseases. Read more at ...

Eyenovia said it is ending the Phase 3 study of a drug-device combination of low-dose atropine in its Optejet dispensing platform in pediatric progressive myopia and exploring its strategic options ...

Eyenovia said Friday it plans to cut half of its workforce after results from a Phase 3 study missed their primary endpoint. The pharmaceutical company had 57 full-time employees as of March 15. There ...

CHAPERONE is Eyenovia’s Phase 3 study evaluating its proprietary drug-device combination of low-dose atropine in the Company’s Optejet dispensing platform as a potential treatment for pediatric ...

On Friday, Eyenovia, Inc. (NASDAQ:EYEN) stock is trading lower after an update from the Phase 3 CHAPERONE study evaluating ...

Eyenovia (EYEN) announced that a review of the CHAPERONE data by an independent Data Review Committee found that the trial is not meeting its ...

Atropine was administered orally in a dose ... drugs should be further investigated in the management of very tall children.

OBJECTIVE: To describe the effects of combined trimedoxime (TMB4) and atropine poisoning from automatic injectors (AI) in children. STUDY DESIGN: Data was collected from two sources: calls to the ...